Malignant germ cell tumors in men infected with the human immunodeficiency virus

Natural history and results of therapy

J. M. Timmerman, Donald W Northfelt, E. J. Small

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: To determine how men infected with the human immunodeficiency virus (HIV) tolerate and respond to treatment for malignant germ cell tumors (GCTs), and how GCT histology and stage compare among HIV-infected versus non-HIV-infected men. Patients and Methods: Two hundred ninety-four cases of GCT diagnosed or treated from 1980 to 1993 were reviewed. Nine new cases among HIV-infected men were identified; these were analyzed together with six cases previously reported from our institution. Results: Low-stage tumors (stages I and IIA) comprised 67% of HIV-infected and 63% of non- HIV-infected cases. Sixty-seven percent of HIV-infected cases were seminomas versus 51% of non-HIV-infected cases. Ten patients had AIDS at the time of GCT diagnosis. Five patients underwent radiation therapy and one patient underwent retroperitoneal lymphadenectomy without complications. Seven patients received chemotherapy with four cycles of cisplatin, etoposide, and bleomycin (PEB) or cisplatin, vinblastine, and bleomycin (PVB) without excess cytopenias or new opportunistic infections. Of seven patients treated for advanced disease, there were five complete and two partial responses. Six patients have died of AIDS at a median of 20 months after diagnosis of GCT. The median follow-up time for surviving patients has been 42 months (range, 8 to 87) and all but one remain without evidence of active disease. In no case was a patient's HIV disease classification altered by antitumor therapy. Conclusion: The natural history of GCTs is comparable in HIV-infected and non-HIV-infected men and standard therapy including orchiectomy, retroperitoneal lymph node dissection, radiation therapy, and chemotherapy is well tolerated.

Original languageEnglish (US)
Pages (from-to)1391-1397
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Natural History
HIV
Therapeutics
Bleomycin
Viruses
Lymph Node Excision
Cisplatin
Acquired Immunodeficiency Syndrome
Radiotherapy
Drug Therapy
Seminoma
Orchiectomy
Vinblastine
Opportunistic Infections
Etoposide
Virus Diseases
Histology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Malignant germ cell tumors in men infected with the human immunodeficiency virus : Natural history and results of therapy. / Timmerman, J. M.; Northfelt, Donald W; Small, E. J.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 1995, p. 1391-1397.

Research output: Contribution to journalArticle

@article{802141d61d5e4e71b48276f71fb534f2,
title = "Malignant germ cell tumors in men infected with the human immunodeficiency virus: Natural history and results of therapy",
abstract = "Purpose: To determine how men infected with the human immunodeficiency virus (HIV) tolerate and respond to treatment for malignant germ cell tumors (GCTs), and how GCT histology and stage compare among HIV-infected versus non-HIV-infected men. Patients and Methods: Two hundred ninety-four cases of GCT diagnosed or treated from 1980 to 1993 were reviewed. Nine new cases among HIV-infected men were identified; these were analyzed together with six cases previously reported from our institution. Results: Low-stage tumors (stages I and IIA) comprised 67{\%} of HIV-infected and 63{\%} of non- HIV-infected cases. Sixty-seven percent of HIV-infected cases were seminomas versus 51{\%} of non-HIV-infected cases. Ten patients had AIDS at the time of GCT diagnosis. Five patients underwent radiation therapy and one patient underwent retroperitoneal lymphadenectomy without complications. Seven patients received chemotherapy with four cycles of cisplatin, etoposide, and bleomycin (PEB) or cisplatin, vinblastine, and bleomycin (PVB) without excess cytopenias or new opportunistic infections. Of seven patients treated for advanced disease, there were five complete and two partial responses. Six patients have died of AIDS at a median of 20 months after diagnosis of GCT. The median follow-up time for surviving patients has been 42 months (range, 8 to 87) and all but one remain without evidence of active disease. In no case was a patient's HIV disease classification altered by antitumor therapy. Conclusion: The natural history of GCTs is comparable in HIV-infected and non-HIV-infected men and standard therapy including orchiectomy, retroperitoneal lymph node dissection, radiation therapy, and chemotherapy is well tolerated.",
author = "Timmerman, {J. M.} and Northfelt, {Donald W} and Small, {E. J.}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "1391--1397",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Malignant germ cell tumors in men infected with the human immunodeficiency virus

T2 - Natural history and results of therapy

AU - Timmerman, J. M.

AU - Northfelt, Donald W

AU - Small, E. J.

PY - 1995

Y1 - 1995

N2 - Purpose: To determine how men infected with the human immunodeficiency virus (HIV) tolerate and respond to treatment for malignant germ cell tumors (GCTs), and how GCT histology and stage compare among HIV-infected versus non-HIV-infected men. Patients and Methods: Two hundred ninety-four cases of GCT diagnosed or treated from 1980 to 1993 were reviewed. Nine new cases among HIV-infected men were identified; these were analyzed together with six cases previously reported from our institution. Results: Low-stage tumors (stages I and IIA) comprised 67% of HIV-infected and 63% of non- HIV-infected cases. Sixty-seven percent of HIV-infected cases were seminomas versus 51% of non-HIV-infected cases. Ten patients had AIDS at the time of GCT diagnosis. Five patients underwent radiation therapy and one patient underwent retroperitoneal lymphadenectomy without complications. Seven patients received chemotherapy with four cycles of cisplatin, etoposide, and bleomycin (PEB) or cisplatin, vinblastine, and bleomycin (PVB) without excess cytopenias or new opportunistic infections. Of seven patients treated for advanced disease, there were five complete and two partial responses. Six patients have died of AIDS at a median of 20 months after diagnosis of GCT. The median follow-up time for surviving patients has been 42 months (range, 8 to 87) and all but one remain without evidence of active disease. In no case was a patient's HIV disease classification altered by antitumor therapy. Conclusion: The natural history of GCTs is comparable in HIV-infected and non-HIV-infected men and standard therapy including orchiectomy, retroperitoneal lymph node dissection, radiation therapy, and chemotherapy is well tolerated.

AB - Purpose: To determine how men infected with the human immunodeficiency virus (HIV) tolerate and respond to treatment for malignant germ cell tumors (GCTs), and how GCT histology and stage compare among HIV-infected versus non-HIV-infected men. Patients and Methods: Two hundred ninety-four cases of GCT diagnosed or treated from 1980 to 1993 were reviewed. Nine new cases among HIV-infected men were identified; these were analyzed together with six cases previously reported from our institution. Results: Low-stage tumors (stages I and IIA) comprised 67% of HIV-infected and 63% of non- HIV-infected cases. Sixty-seven percent of HIV-infected cases were seminomas versus 51% of non-HIV-infected cases. Ten patients had AIDS at the time of GCT diagnosis. Five patients underwent radiation therapy and one patient underwent retroperitoneal lymphadenectomy without complications. Seven patients received chemotherapy with four cycles of cisplatin, etoposide, and bleomycin (PEB) or cisplatin, vinblastine, and bleomycin (PVB) without excess cytopenias or new opportunistic infections. Of seven patients treated for advanced disease, there were five complete and two partial responses. Six patients have died of AIDS at a median of 20 months after diagnosis of GCT. The median follow-up time for surviving patients has been 42 months (range, 8 to 87) and all but one remain without evidence of active disease. In no case was a patient's HIV disease classification altered by antitumor therapy. Conclusion: The natural history of GCTs is comparable in HIV-infected and non-HIV-infected men and standard therapy including orchiectomy, retroperitoneal lymph node dissection, radiation therapy, and chemotherapy is well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0029036857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036857&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1391

EP - 1397

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -